Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home News

FDA Okays Tablet Version of Acalabrutinib for All Indications

admin by admin
August 6, 2022
in News


The US Food and Drug Administration has approved AstraZeneca’s new tablet formulation of acalabrutinib (Calquence) for all current indications of the capsule version.

These include adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma (MCL).

Approval of the tablet formulation of the selective Bruton’s tyrosine kinase inhibitor was based on the ELEVATE-PLUS trials, which showed bioequivalence with the capsule. The tablet had the same efficacy and safety profile with the same dosing strength and schedule, AstraZeneca said in a press release.

The benefit of the tablet formulation is that patients with acid reflux and other problems can take it with proton pump inhibitors, antacids, and H2-receptor antagonists, the company noted.

M. Alexander Otto is a physician assistant with a master’s degree in medical science. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape and is an MIT Knight Science Journalism fellow. Email: aotto@mdedge.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Credits:

Lead image: AstraZeneca

Cite this: FDA Approves Tablet Formulation of Acalabrutinib (Calquence) for CLL, SLL, and MCL – Medscape – Aug 05, 2022.





Source link

Tags: chronic lymphocytic leukemiafdahematologyphysician assistantsu.s. food and drug administrationunited states food and drug administration
Previous Post

US Declares Monkeypox a Public Health Emergency

Next Post

Lifestyle May Be Key to Helping You Avoid Dementia

Next Post

Lifestyle May Be Key to Helping You Avoid Dementia

Recommended

When Older Dogs’ Hearing Fades, Risk of Dementia Rises

August 14, 2022

Which Source of Dietary Fiber Works Best?

August 6, 2022

Don't miss it

Pharmaceutical

Health Bulletin 18/August/2022

August 18, 2022
Medicines & Healthy Lifestyle

FDA Approves Citrate-Free, High Concentration of Hadlima

August 18, 2022
Medicines & Healthy Lifestyle

Use Of Sleep Medications Among Americans Declining In Recent Years

August 18, 2022
News

Fake Positive Reviews; Low Quality Guidelines; and CDC Reorg

August 18, 2022
Pharmaceutical

Organ transplantation is at a crossroads. Major reform is needed

August 18, 2022
News

Do Wind Instruments Spread COVID?

August 18, 2022

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.